

WEDNESDAY 11th FEBRUARY 2015 COMMENCING 10.30 AM

AT [THE ANGEL HOTEL](#), ABERGAVENNY, NP7 5EN

AGENDA

Enclosure

1. **Welcome and introduction**
2. **Apologies**
3. **Declarations of interest**
4. **Minutes of previous meeting**

1/AWMSG/0215

To protect commercial confidentiality, the first appraisal will be conducted in private.

5. **Appraisal 1: Full Submission (WPAS)**
Aflibercept (Zaltrap[®]▼) in combination with irinotecan/5
fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults
with metastatic colorectal cancer (MCRC) that is resistant to or has
progressed after an oxaliplatin containing regimen

2/AWMSG/0215
Appendices

The meeting will now open to the public (approx 11.15am)

6. **Chairman's report (verbal update)**
7. **Appraisal 2 - Full Submission**
Lurasidone (Latuda[®]) for the treatment of schizophrenia in adults
aged 18 years and over
8. **National Prescribing Indicators 2014–2015: Analysis of
Prescribing Data to September 2014**
9. **National Prescribing Indicators (NPIs) 2015–2016**
10. **NPIs 2015–2016 Supporting Information for Prescribers**
11. **Review of the AWMSG National Audit: Focus on Antibiotic
Prescribing 2013–2015**

3/AWMSG/0215
Appendices

4/AWMSG/0215

5/AWMSG/0215

6/AWMSG/0215

7/AWMSG/0215

- | | | |
|-----|--|----------------------------|
| 12. | Appraisal 3: Full Submission
Umeclidinium/vilanterol (as trifenate) (Anoro® Ellipta®) for
maintenance bronchodilator treatment to relieve symptoms in adult
patients with chronic obstructive pulmonary disease | 8/AWMSG/0215
Appendices |
| 13 | Feedback from AWPAG Meeting 10th December 2014 | 9/AWMSG/0215 |
| 14. | Respiratory Prescribing Analysis with Cluster Level
Comparators | 10/AWMSG/0215 |
| 15. | All Wales Advice on the Role of Oral Anticoagulants –
Implementation Documents | 11/AWMSG/0215 |
| 16. | Eculizumab for treating atypical haemolytic uraemic syndrome | 12/AWMSG/0215 |

Date of next meeting:

Wednesday 25th March 2015 at the Angel Hotel, Abergavenny